Latest Financials News

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Ainsworth Game Technology reported a steady half-year profit of $4.9 million on a 25% revenue increase, driven by strong domestic sales and new product launches, while navigating regional challenges and a looming Novomatic takeover bid.

Redcastle Resources Limited has resumed trading on the ASX following key announcements about a joint venture farm-out, a strategic placement, and a major gold project acquisition.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.

WOTSO’s FY25 results reveal a robust 14% increase in underlying EBITDA, driven by its expanding flexible workspace portfolio now spanning 31 locations. Strategic investments and partnerships underpin a confident outlook toward $58 million revenue by FY30.

Saunders International reported a modest revenue dip and sharp profit decline in FY2025, offset by a transformative acquisition that expands its water infrastructure footprint and doubles its project pipeline.

Frontier Digital Ventures has uncovered apparent misappropriation of approximately USD 430,000 within its Colombian business, Fincaraiz, prompting an ongoing investigation and operational safeguards.

Vicinity Centres confirms its distribution reinvestment plan will apply to the FY25 final distribution, offering investors a 1% discount on new securities issued under the plan.

WOTSO’s FY2025 results reveal an 11% revenue decline but a significantly reduced net loss, alongside a raised distribution payout, signaling cautious optimism amid market challenges.

Saunders International reported a slight revenue dip and a sharp EBITDA decline in FY2025, offset by a transformative acquisition that dramatically expands its order book and pipeline.

Vicinity Centres reported a robust FY25 with statutory net profit surging to $1 billion, driven by strategic portfolio repositioning and strong retail sales growth. The company’s focus on premium assets and disciplined capital management sets the stage for continued growth in FY26.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.